Kb Financial Partners, LLC Genmab A/S Transaction History

Kb Financial Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$26.83 - $38.57 $15,373 - $22,100	-573 Closed	0 $0
Q4 2021 Feb 18, 2022	BUY	$35.87 - $47.12 $20,553 - $26,999	573 New	573 $23,000
Q3 2021 Nov 16, 2021	SELL	$41.55 - $48.72 $24,306 - $28,501	-585 Closed	0 $0
Q2 2021 Aug 17, 2021	SELL	$32.88 - $44.57 $2,301 - $3,119	-70 Reduced 10.69%	585 $24,000
Q1 2021 Jun 08, 2021	BUY	$30.92 - $44.4 $20,252 - $29,082	655 New	655 $22,000

238

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.4B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Kb Financial Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Kb Financial Partners, LLC with notifications on news.